Expertise in
8
conditions

David Brassat

CHU Purpan
Toulouse, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
CHU Purpan
Toulouse, FR 

Overview

David Brassat practices practicing medicine in Toulouse, France.

Mr. Brassat is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), CACH Syndrome, Transverse Myelitis, and Optic Neuritis.

He is actively involved in clinical research, co-authoring 97 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

CHU Purpan
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Enrollment Status: Recruiting
Publish Date: January 05, 2026
Intervention Type: Other
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Teriflunomide [Aubagio]
Study Phase: Phase 3
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
Enrollment Status: Completed
Publish Date: April 24, 2020
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort
Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort
Enrollment Status: Terminated
Publish Date: January 03, 2018
Intervention Type: Other
View 8 Less Clinical Trials

97 Total Publications

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
Journal: Brain : a journal of neurology
Published: June 14, 2025

Frequently Asked Questions about David Brassat

Is David Brassat a top-rated expert for Multiple Sclerosis (MS)?

MediFind is an objective health platform that identifies experts based on real-world data. David Brassat is classified as an Distinguished expert for Multiple Sclerosis (MS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does David Brassat participate in research or clinical trials?

Yes. David Brassat has published 97 articles and abstracts on conditions like Multiple Sclerosis (MS). You can view a list of David Brassat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Brassat's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile